Stange A W, Furman F J, Hilmas D E
Health Effects Department, Rocky Flats Environmental Technology Site, Golden, Colorado 80402-0464, USA.
Environ Health Perspect. 1996 Oct;104 Suppl 5(Suppl 5):981-6. doi: 10.1289/ehp.96104s5981.
The Rocky Flats Beryllium Health Surveillance Program (BHSP), initiated in June 1991, was designed to provide medical surveillance for current and former employees exposed to beryllium. The BHSP identifies individuals who have developed beryllium sensitivity using the beryllium lymphocyte proliferation test (BeLPT). A detailed medical evaluation to determine the prevalence of chronic beryllium disease (CBD) is offered to individuals identified as beryllium sensitized or to those who have chest X-ray changes suggestive of CBD. The BHSP has identified 27 cases of CBD and another 74 cases of beryllium sensitization out of 4268 individuals tested. The distribution of BeLPT values for normal, sensitized, and CBD-identified individuals is described. Based on the information collected during the first 3 1/3 years of the BHSP, the BeLPT is the most effective means for the early identification of beryllium-sensitized individuals and to identify individuals who may have CBD. The need for BeLPT retesting is demonstrated through the identification of beryllium sensitization in individuals who previously tested normal. Posterior/anterior chest X-rays were not effective in the identification of CBD.
落基弗拉特铍健康监测项目(BHSP)始于1991年6月,旨在为当前和曾经接触过铍的员工提供医学监测。BHSP使用铍淋巴细胞增殖试验(BeLPT)来识别已产生铍敏感性的个体。对于被确定为铍敏感或胸部X光检查有提示慢性铍病(CBD)变化的个体,会提供详细的医学评估以确定CBD的患病率。在接受检测的4268人中,BHSP已识别出27例CBD病例和另外74例铍敏感病例。描述了正常、敏感和已确诊CBD个体的BeLPT值分布情况。根据BHSP前3又1/3年收集的信息,BeLPT是早期识别铍敏感个体以及识别可能患有CBD个体的最有效手段。通过在之前检测正常的个体中识别出铍敏感性,证明了进行BeLPT复测的必要性。后前位胸部X光检查在识别CBD方面效果不佳。